AKBA
USDAkebia Therapeutics Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$2.100
Kõrge
$2.145
Madal
$2.070
Maht
4.47M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
563.4M
Tööstusharu
Drug Manufacturers - Specialty & Generic
Riik
United States
Kauplemisstatistika
Keskmine maht
4.04M
Börs
NCM
Valuuta
USD
52 nädala vahemik
Seotud uudised
Akebia Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $6
HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics with a Buy and lowers the price target from $8 to $6.
BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $5
BTIG analyst Julian Harrison maintains Akebia Therapeutics with a Buy and lowers the price target from $10 to $5.
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced
Seotud aktsiad
RIV
RiverNorth Opportunities Fund Inc.
ZS
Zscaler Inc.
KMPB
Kemper Corporation 5.875% Fixed-Rate Reset Junior Subordinated Debentures due 2062
GLLIR
Globalink Investment Inc. Rights
DTG
DTE Energy Company 2021 Series E 4.375% Junior Subordinated Debentures
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.